Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity.

ABSTRACT:

Introduction

Dexrazoxane (DZR) has been used to prevent cardiotoxicity from doxorubicin (DOX), particularly in younger patients with cancer and those with pre-existing cardiac dysfunction. Herein, we sought to further define the role of DZR by evaluating its capacity to mitigate cardiotoxicity in patients actively receiving DOX, while also assessing concomitant toxicities.

Materials and methods

We conducted a retrospective, propensity-matched cohort study at a single academic center, comparing outcomes between patients treated with DZR plus DOX and those who received DOX alone. Patients were matched by age, sex, and cumulative lifetime dose of DOX. Cardiotoxicity was assessed as the change in ejection fraction (EF) during and after treatment. To evaluate associations between

SUBMITTER: Neiman ZM 

PROVIDER: S-EPMC12308200 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature